The European Medicines Agency said Monday it would undertake a review into a number of drugs used to treat obesity and diabetes after it was reported some patients experienced thoughts of suicide or self-harm.

In a statement, the regulator said its safety committee, or PRAC, was “currently evaluating the risk of suicidal thoughts and thoughts of self-harm in patients who used a semaglutide — or liraglutide —containing medicine for weight loss.”

“The review is being carried out in the context of a signal procedure raised by the Icelandic Medicines Agency following three case reports,” the EMA said. “A signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation.”

The EMA said the case reports “included 2 cases of suicidal thoughts, one following the use of Saxenda and one after Ozempic. One additional case reported thoughts of self-injury with Saxenda.”

Read more at CNBC >>